Quantitative assessment of olfactory dysfunction accurately detects asymptomatic COVID-19 carriers

Abstract

Background COVID-19 threatens the global community because a large fraction of infected people are asymptomatic, yet can effectively transmit SARS-CoV-2. Finding and isolating these silent carriers is a crucial step in confining the spread of the disease. A sudden loss of the sense of smell has been self-reported by COVID-19 patients across different countries, consistent with expression of the molecular factors mediating SARS-CoV-2 uptake into human olfactory epithelial supporting cells. However, precise quantification of olfactory loss in asymptomatic COVID-19 carriers is missing to date. Methods To quantify olfactory functions in asymptomatic COVID-19 patients, we designed an olfactory-action meter that determines detectability indices at different odor concentrations and an olfactory matching accuracy score using monomolecular odors. The optimization of test parameters allowed us to reliably and accurately assess olfactory deficits in a patient within 20 minutes. Findings Measurement of detection indices at low concentrations revealed a 50% reduction in asymptomatic COVID-19 carriers. Further, patients with better detection scores showed significantly reduced olfactory matching accuracies compared to normal healthy subjects. Our quantification of olfactory loss, considering all parameters, identified 82% of the asymptomatic SARS-CoV-2 carriers with olfactory deficits. However, on subjective evaluation, only 15% of the patients noticed a compromised ability to smell. Interpretation Compromised olfactory fitness can serve as a strong basis for identifying asymptomatic COVID-19 patients. Detailed design specifications and protocols provided here should enable the development of a sensitive, fast, and economical screening strategy that can be administered to large populations to prevent the rapid spread of COVID-19. Funding This work was supported by the DBT – Wellcome Trust India Alliance intermediate grant (IA/I/14/1/501,306 to N.A.) and UGC NET Fellowship (A.B.). All the funding sources played no roles in the study.

MOATAI-VIR - an AI algorithm that predicts severe adverse events and molecular features for COVID-19’s complications

“…The olfactory signaling pathway is associated with 18/19 clinical manifestation groups from the GWAS results. This pathway involves enzymatic activity that initiates the binding of an odorant molecule to a receptor resulting in an electrical signal that is transmitted to the brain(23). The olfactory signaling pathway was the top pathway for the asthma exacerbation, hematologic, respiratory failure, and gastrointestinal GWAS clinical manifestations.…”

“…The olfactory signaling pathway was the top pathway for the asthma exacerbation, hematologic, respiratory failure, and gastrointestinal GWAS clinical manifestations. There is clinical evidence that some individuals infected with SARS-CoV-2 experience a loss of smell and taste(23). Furthermore, it has been found that olfactory receptors may be an alternative SARS-CoV-2 entry into the local host cells, which may lead to its spread into the central nervous system(24).…”

SCENTinel 1.0: development of a rapid test to screen for smell loss

“…Altogether, our findings support the idea that SCENTinel 1.0 represents a rapid, accurate, flexible, and cost-effective tool to deploy a smell test on large scale population surveillance efforts. The development of SCENTinel 1.0 has been spurred by the new sudden loss of smell that characterizes COVID-19, including among nominally asymptomatic individuals, many of whom had smell loss but were not aware of before receiving an objective olfactory test (Gözen et al, 2020;Bhattacharjee et al, 2020) . Yet, the large-scale availability of a validated rapid smell test can benefit not only health emergencies such as COVID-19, but also be used in early detection and monitoring of a variety of clinical conditions, including psychiatric, neurological and neurodegenerative disorders.…”

Tracking smell loss to identify healthcare workers with SARS-CoV-2 infection

“…Olfactory impairment is a common manifestation of COVID-19, with meta-analyses indicating a prevalence of 77-86% in studies using standardized olfactory testing [8][9][10][11]. Among patients with COVID-19 assessed for smell loss, 41% and 98% had impaired tests of olfaction on two different tests of olfactory function [12,13], suggesting that smell loss may aid in COVID-19 case identification [14].…”